

Date: 07.10.2026

To
BSE Limited
Dept. of Corporate Services,
Floor 25, PJ Towers,
Dalal Street,
Mumbai-400001.

Scrip Code: 526445

Dear Sir/Madam,

Subject: Outcome of the Board Meeting 07th October, 2026.

Ref: Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

With reference to our intimation letter dated September 30, 2026 under Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we wish to inform that at the meeting of Board of Directors held today i.e., on Wednesday, October 07, 2026, the Directors have inter-alia, recorded the following:

1. The approval of Unaudited Financial Results (Standalone and Consolidated) of the Company, for the quarter ended June 30, 2026, as recommended by the Audit Committee at their Meeting held today, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The statutory auditors have reviewed the financial results and given unmodified opinion.
2. Approved the reconstitution of the following Committees of the Board with effect from today i.e. 07th October, 2026.

AUDIT COMMITTEE:			
S. No	Name of the Director	Designation in Committee	Category of Directorship
1	Mr. Nangavaram Mahadevan Ranganathan	Chairman	Independent Director
2	Mr. Swaminathan Govindarajan	Member	Whole-time Director
3	Ms. Bokara Nagarajan Padmaja Priyadarshini	Member	Independent Director

STAKEHOLDER RELATIONSHIP COMMITTEE:			
S. No	Name of the Director	Designation in Committee	Category of Directorship
1	Mr. Nangavaram Mahadevan Ranganathan	Chairman	Independent Director
2	Mr. Swaminathan Govindarajan	Member	Whole-time Director
3	Ms. Bokara Nagarajan Padmaja Priyadarshini	Member	Independent Director

RIGHTS ISSUE COMMITTEE:			
S. No	Name of the Director	Designation in Committee	Category of Directorship
1	Mr. Nangavaram Mahadevan Ranganathan	Chairman	Independent Director
2	Mr. Swaminathan Govindarajan	Member	Whole-time Director
3	Mr. Kasiraman Sayee Sundar	Member	Managing Director

The Board Meeting commenced at 03:45 P.M. and concluded at 05:45 P.M. The necessary arrangements are in place to publish the audited financial results in the newspapers. The said financial results will also be available on company's website <https://indrayani.com> and also on BSE website <https://www.bseindia.com/stock-share-price/indrayani-biotechltd/indranib/526445/>.

Kindly take the above information on record.

Thanking you,
Yours faithfully,
For **Indrayani Biotech Limited**

SWAMINATHAN Digitally signed by
GOVINDARAJA SWAMINATHAN
N GOVINDARAJAN

Swaminathan Govindarajan
Whole-time Director
DIN: 02481041

Encl: As above

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of Indrayani Biotech Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
The Board of Directors,
Indrayani Biotech Limited

We have reviewed the accompanying statement of unaudited standalone financial results of **Indrayani Biotech Limited** ('the Company') for the quarter ended 30th June 2026. This statement, is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the applicable Indian Accounting Standards (Ind AS) specified under Section 133 of the Companies Act, 2013. Our Responsibility is to express a conclusion these financial statements based on our review.

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatements. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

for Venkatesh & Co
Chartered Accountants
FRN : 004636S



CA Dasaraty V

Partner

M No : 026336

UDIN: 26026336BLWJ0Y761

Chennai, 7th October 2026



#32 & 33 Block: I, 3rd Floor Thiru Vi Ka Industrial Estate SIDCO Industrial Estate Guindy Chennai Tamil Nadu 600032.

UnAudited Standalone Statement of Profit and Loss for the year ended 30th June 2026

(Rs in Lakhs Except EPS)

S No	Particulars	Quarter Ended			Year Ended
		6/30/2026	3/31/2026	6/30/2025	3/31/2026
	Income From Operations				
I	Revenue from Operations	415.34	407.98	668.57	2,189.78
II	Other Income	18.77	82.06	89.16	421.25
III	Total Income	434.10	490.04	757.73	2,611.03
	Expenses				
IV	Cost of Materials consumed	188.91	220.15	335.28	1,065.18
	Employee Benefit Expense	100.60	257.93	150.15	701.32
	Finance Cost	76.11	54.17	131.93	394.61
	Depreciation and amortization expense	12.30	18.27	15.25	64.26
	Other expenses	36.81	-90.56	108.09	265.20
	Total Expenses	414.72	459.96	740.70	2,490.57
V	Profit / (loss) before exceptional items and tax	19.38	30.09	17.03	120.46
VI	Exceptional Items	-	-	-	-
	Add : Share of profit In Associates	-	-	-	-
VII	Profit / (loss) before tax	19.38	30.09	17.03	120.46
VIII	Current Tax Expense	4.88	7.69	4.26	30.44
IX	Deferred Tax Expense		20.05		20.05
X	Profit (Loss) for the period from continuing operations (VII-VIII-IX)	14.50	2.35	12.77	69.97
X	Profit (Loss) for the period from discontinued operations	-	-	-	-
XI	Profit (Loss) for the period (IX-X)	14.50	2.35	12.77	69.97
XII	Other Comprehensive Income				
	A (i) Items that will not be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-
	B (i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
XIII	Total Comprehensive Income for the period (XII+XI)(Comprising Profit (Loss) and Other Comprehensive Income for the period)	14.50	2.35	12.77	69.97
	Paid up Equity Share Capital	4,553.63	4,553.63	4,553.63	4,553.63
XIV	Earnings Per Share:				
	(1) Basic	0.03	0.01	0.03	0.15
	(2) Diluted	0.03	0.01	0.03	0.15

Notes:

- The above Standalone financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 07th October 2026 and have been subjected to audit by the Statutory Auditors of the company. The above results have been prepared in accordance with the Indian Accounting Standards-(IndAS) as prescribed under Section133 of the Companies Act 2013, read with Rule3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies(Indian Accounting Standards) Amendment Rules, 2016.
- The financial results are being forwarded to the Bombay Stock Exchange & also available on the company website (www.indrayani.com)
- Previous period figures have been regrouped wherever necessary.
- There is no investor complaint received during the quarter.

For Indrayani Biotech Limited

Digitally signed
SWAMINATHAN by
GOVINDARAJAN SWAMINATHAN
GOVINDARAJAN

Swaminathan Govindarajan

Director

DIN: 02481041

Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of Indrayani Biotech Limited Pursuant to the regulation 33 of the SEBI (Listing Obligations and disclosure requirements) regulations, 2015, as amended

To
The Board of Directors
Indrayani Biotech Limited

We have reviewed the accompanying Statement of Consolidated Financial Results of Indrayani Biotech Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") and its share of the net profit / loss after tax and total comprehensive income / loss of its associates for the quarter ended **30th June, 2026** ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been compiled from the related consolidated financial statements which has been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, read with the Companies (Indian Accounting Standards) Rules, 2015, as amended ("Ind AS"), and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatements. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement includes the results of the entities mentioned in the Annexure – I, is presented in accordance with the requirements of Regulation 33 of the Listing Regulations, as amended;

Based on our review conducted and procedures performed as stated in paragraph above and based on the consideration of the reports of the management referred to in paragraph below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



We did not review the financial statement / financial information of **7 Subsidiaries and 2 step down subsidiaries** included in the consolidated unaudited financial results, whose interim financial information for the quarter ended 30th June, 2026 reflects total revenues of **₹ 3,405.80 Lakhs**, total comprehensive profit / (loss) of **₹ 39.50 Lakhs** for the period ended on that date as considered in the consolidated financial results.

This financial information have been reviewed by the Management and our opinion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, associates and joint ventures, is based solely on the reports of the Management and the procedures performed by us as stated in paragraph mentioned above.

for Venkatesh & Co

Chartered Accountants

FRN : 004636S



CA Dasaraty V

Partner

M No : 026336

UDIN: 26026336UPGMXN7617

Chennai, 7th October 2026

Annexure I to the Audit Report

List of subsidiaries, associates and joint ventures included in the consolidated Quarterly Unaudited financial results:

S. No.	Name of the entity	Relationship
1	IBL Health Care Limited	Subsidiary
2	HSL Agri Solutions Limited	Subsidiary
3	HSL Prime Properties Private Limited	Subsidiary
4	Healthway India Private Limited	Step Down Subsidiary
5	Dindigul Farm Product Limited*	Subsidiary (31.34%)*
6	Matrix Boilers Private Limited	Subsidiary
7	IBL Investments Limited	Subsidiary
8	IBL Social Foundation	Subsidiary
9	Kniss Laboratories Private Limited	Step Down Subsidiary

***Consolidation Comprises of Financial results of Dindigul Farm Product Limited by the virtue of Control established over Board of Directors and decisions of management.**



#32 & 33 Block: I, 3rd Floor Thiru Vi Ka Industrial Estate SIDCO Industrial Estate Guindy Chennai Tamil Nadu 600032.

UnAudited Consolidated Statement of Profit and Loss for the year ended 30th June 2026

(Rs in Lakhs Except EPS)

S No	Particulars	Quarter Ended			Year Ended
		6/30/2026	3/31/2026	6/30/2025	3/31/2026
	Income From Operations				
I	Revenue from Operations	3,770.55	3,776.42	2,910.37	13,783.12
II	Other Income	159.10	88.39	105.62	457.22
III	Total Income	3,929.65	3,864.81	3,015.99	14,240.35
	Expenses				
IV	Cost of Materials consumed	3,246.31	2,527.44	2,075.82	9,407.32
	Change in Inventories	-41.71	-	-	-
	Employee Benefit Expense	292.35	429.84	269.23	1,416.15
	Finance Cost	137.46	307.52	217.08	960.08
	Depreciation and amortization expense	109.55	113.30	85.82	430.14
	Other expenses	126.81	597.90	347.17	1,996.66
	Total Expenses	3,870.76	3,976.00	2,995.12	14,210.36
V	Profit / (loss) before exceptional items and tax	58.88	-111.19	20.87	29.99
VI	Exceptional Items	-	-	-	-
	Add : Share of profit In Associates	-	-	-	-
VII	Profit / (loss) before tax	58.88	-111.19	20.87	29.99
VIII	Current Tax Expense	4.88	-17.30	5.22	5.45
IX	Deferred Tax Expense		-191.49	-	-191.49
X	Profit (Loss) for the period from continuing operations (VII-VIII)	54.00	97.60	15.65	216.03
X	Profit (Loss) for the period from discontinued operations	-	-	-	-
XI	Profit (Loss) for the period (VII-VIII)	54.00	97.60	15.65	216.03
XII	Other Comprehensive Income				
	A (i) Items that will not be reclassified to profit or loss	-	-	-	0.78
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-
	B (i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
XIII	Total Comprehensive Income for the period (XII+XI)(Comprising Profit (Loss) and Other Comprehensive Income for the period)	54.00	97.60	15.65	216.81
	Comprehensive Income for the period attributable to the Owners of the Company	26.22	-18.92	10.24	37.81
	Total Comprehensive Income for the period attributable to the Non Controlling Interest	27.78	117.31	5.41	179.00
	Paid up Equity Share Capital	4,553.63	4,553.63	4,553.63	4,553.63
XIV	Earnings Per Share:				
	(1) Basic	0.06	-0.04	0.02	0.08
	(2) Diluted	0.06	-0.04	0.02	0.08

Notes:

- The above Consolidated financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 07th October 2026 and have been subjected to audit by the Statutory Auditors of the company. The above results have been prepared in accordance with the Indian Accounting Standards-(IndAS) as prescribed under Section 133 of the Companies Act 2013, read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016.
- The financial results are being forwarded to the Bombay Stock Exchange & also available on the company website (www.indrayani.com)
- Previous period figures have been regrouped wherever necessary.
- There is no investor complaint received during the quarter.

For Indrayani Biotech Limited

SWAMINATHAN
GOVINDARAJAN

Digitally signed by
SWAMINATHAN
GOVINDARAJAN

Swaminathan Govindarajan

Director

DIN: 02481041